Xencor Inc. Files Definitive Proxy Statement

TL;DR

<b>Xencor Inc. has filed its Definitive Proxy Statement for the period ending December 31, 2023, outlining its strategy in developing biologic medicines using XmAb® technology.</b>

AI Summary

Xencor Inc (XNCR) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Xencor Inc. filed a Definitive Proxy Statement (DEF 14A) on April 24, 2024. The filing covers the period ending December 31, 2023, with prior periods for 2022, 2021, and 2020 also referenced. The company utilizes XmAb® protein engineering technologies to develop biologic medicines for cancer and other serious diseases. Xencor's strategy involves advancing a broad clinical-stage portfolio of antibody-based drug candidates. The company is focused on developing targeted T-cell engaging bispecific antibodies for solid tumors.

Why It Matters

For investors and stakeholders tracking Xencor Inc, this filing contains several important signals. This filing provides stockholders with information regarding the company's governance, executive compensation, and strategic direction, particularly its focus on advancing a pipeline of T-cell engaging bispecific antibodies. The proxy statement details Xencor's approach to developing innovative antibody-based therapies, highlighting its protein engineering expertise and clinical-stage portfolio aimed at treating challenging diseases like cancer.

Risk Assessment

Risk Level: low — Xencor Inc shows low risk based on this filing. The filing is a routine DEF 14A, providing information on corporate governance and strategy rather than new financial results or material events, indicating a low level of immediate market impact.

Analyst Insight

Stockholders should review the proxy statement for details on executive compensation, board nominations, and the company's strategic priorities in advancing its clinical-stage antibody-based drug candidates.

Key Numbers

• 2024-04-24 — Filing Date (DEF 14A Filing Date)
• 2023-12-31 — Reporting Period End (Conformed Period of Report)
• 2022-12-31 — Prior Period End (Referenced Fiscal Year End)
• 2021-12-31 — Prior Period End (Referenced Fiscal Year End)
• 2020-12-31 — Prior Period End (Referenced Fiscal Year End)

Key Players & Entities

• Xencor Inc. (company) — Registrant Name
• XmAb® (other) — Protein engineering technology
• DEF 14A (other) — Filing Type
• 2024-04-24 (date) — Filing Date
• 2023-12-31 (date) — Reporting Period End Date
• 465 N. HALSTEAD ST. SUITE 200, PASADENA, CA 91107 (address) — Business Address

FAQ

Industry Context

Xencor operates in the pharmaceutical preparations industry, focusing on developing advanced biologic medicines using proprietary protein engineering technologies.

Regulatory Implications

The filing is a standard DEF 14A, subject to SEC regulations under the 1934 Act, concerning proxy solicitations and corporate disclosures.

What Investors Should Do

1. Review the proxy statement for details on director nominations and corporate governance proposals.
2. Examine executive compensation disclosures and any proposed equity incentive plans.
3. Understand the company's strategic priorities for advancing its clinical-stage drug pipeline, particularly T-cell engaging bispecific antibodies.

Key Dates

• 2024-04-24: DEF 14A Filing — Definitive Proxy Statement filed

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure for annual meetings and does not represent a change from previous filings of the same type, but provides updated information for the current reporting period.

Key Financial Figures

• $215.0 million — ales of two marketed XmAb medicines for $215.0 million. Proceeds from the monetization provide
• $12,500 — paid its customary fee of approximately $12,500, plus out-of-pocket expenses. We may al

Filing Documents

• xncr-20240423.htm (DEF 14A) — 928KB
• xncr-20240423_g1.jpg (GRAPHIC) — 17KB
• xncr-20240423_g2.jpg (GRAPHIC) — 5KB
• xncr-20240423_g3.jpg (GRAPHIC) — 1KB
• xncr-20240423_g4.jpg (GRAPHIC) — 28KB
• xncr-20240423_g5.jpg (GRAPHIC) — 29KB
• xncr-20240423_g6.jpg (GRAPHIC) — 147KB
• xncr-20240423_g7.jpg (GRAPHIC) — 168KB
• xncr-20240423_g8.jpg (GRAPHIC) — 111KB
• 0001326732-24-000017.txt (&nbsp;) — 2713KB
• xncr-20240423.xsd (EX-101.SCH) — 2KB
• xncr-20240423_def.xml (EX-101.DEF) — 3KB
• xncr-20240423_lab.xml (EX-101.LAB) — 3KB
• xncr-20240423_pre.xml (EX-101.PRE) — 2KB
• xncr-20240423_htm.xml (XML) — 57KB

Executive Compensation Discussion and Analysis

Executive Compensation Discussion and Analysis 30 Report of the Human Capital Management & Compensation Committee of the Board of Directors 42 Ratio of Annual Compensation for the CEO to Our Median Employee 52

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 53 Pay versus Performance 55 Delinquent Section 16(a) Reports 58 Householding of Proxy Materials 59 Other Matters 60 2 XENCOR, INC. 465 North Halstead, Suite 200 Pasadena, CA 91107 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To be held on June 13, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the "SEC"), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the "Notice") because the Board of Directors (sometimes referred to as "our Board" or "the Board") of Xencor, Inc. ("Xencor" or the "Company") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about May 1, 2024 to all stockholders of record entitled to vote at the annual meeting. Will I receive any other proxy materials by mail? We may send you a proxy card, along with a second Notice, on or after May 1, 2024. How can I attend the annual meeting? The meeting will be held on Thursday, June 13, 2024 at 1:30 p.m. local time at the Company's headquarters, 465 North Halstead Street, Suite 200, Pasadena, California 91107. Directions to the annual meeting may be found on our website at: www.xencor.com. Information on how to vote in person at the annual meeting is discussed below. If we decide to make any change in the da

View Full Filing

View this DEF 14A filing on SEC EDGAR